The purpose of the study is to compare how long patients stay free of disease progression when venetoclax is continued for a longer period versus stopping after the initial six‑month course. After the six cycles of the combination, participants are randomly assigned—by chance—to either keep taking venetoclax for up to about 20 cycles or to stop the drug. All participants are then monitored with regular doctor visits, blood tests, and scans to check for any return of disease or side effects. The main outcome measured is progression free survival, which counts the time from random assignment until the disease gets worse or the patient dies.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

The purpose is to find a safe dose of the three‑drug regimen and to see how well it can clear the cancer cells, especially in patients with certain genetic changes such as TP53 or IGHV. Participants will receive the medicines on a planned schedule over several months, with regular check‑ups that may include blood tests and a test called flow cytometry to measure tiny amounts of remaining cancer cells. Safety will be monitored by recording any side effects, and success will be judged by how many patients achieve “MRD negativity,” meaning very few cancer cells can be detected.

Participants in the study will be randomly assigned to receive either Nemtabrutinib or one of the other treatments, Ibrutinib or Acalabrutinib, as chosen by the study doctor. The study will last for a period of time during which participants will take the medication and have regular check-ups to monitor their health and the progress of the disease. The study aims to see how well Nemtabrutinib works compared to the other treatments in terms of how long patients live without the disease getting worse and how many patients respond to the treatment.

Throughout the study, the safety of the participants will be closely monitored, and any side effects will be recorded. The study will also look at how long the benefits of the treatment last and how it affects the overall survival of the participants. This research is important to find better ways to treat CLL and SLL and to improve the quality of life for people living with these conditions.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients. Participants will receive either Zilovertamab Vedotin alone or together with Nemtabrutinib. Zilovertamab Vedotin is given as an injection into a vein, while Nemtabrutinib is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will take place over several weeks, during which participants will be closely monitored by healthcare professionals. They will undergo regular check-ups and tests to assess their response to the treatment and to ensure their safety. The study aims to provide valuable information that could lead to better treatment options for people with these types of blood cancers.

The purpose of the study is to compare how well BGB-16673 works against pirtobrutinib in controlling the disease and to evaluate the safety of both treatments. The study will measure how long patients live without their disease getting worse, which is called progression-free survival. This will be assessed by an independent group of medical experts who will review imaging scans and other test results. The study will also look at overall survival, which means how long patients live overall, and will measure how many patients respond to treatment by having their disease shrink or disappear. Additional measurements include how long the treatment response lasts and how long it takes before patients need another treatment for their disease.

During the study, patients will be randomly assigned to receive either BGB-16673 or pirtobrutinib. Both groups will continue taking their assigned medication for up to 42 months unless their disease gets worse or they experience unacceptable side effects. The study will monitor patients for any unwanted effects of the medications and will track how severe these effects are. Patients will also complete questionnaires about their quality of life, including questions about their physical functioning, symptoms, and overall health status. The study will use computed tomography or magnetic resonance imaging scans to measure disease in patients with small lymphocytic lymphoma, looking for lymph nodes that are larger than normal size.

The purpose of this research is to determine how well NX-5948 works in treating adults with CLL or SLL that has come back or not responded to previous treatments. During the study, participants will receive NX-5948 capsules daily. The maximum daily dose that may be given is 600 milligrams, and treatment may continue for up to 28 days per treatment cycle.

Throughout the study, doctors will monitor participants’ health through regular check-ups and various medical tests. They will look at how the cancer responds to the treatment and keep track of any side effects that may occur. The study will collect information about how long the treatment effects last and how it affects participants’ overall health.

The comparison group receives the standard treatment, which consists of several different medications including rituximab, doxorubicin hydrochloride, vincristine, cyclophosphamide, and prednisolone. In the study group, participants receive pirtobrutinib as an oral tablet and epcoritamab as a subcutaneous injection, which is a method of delivering medication just under the skin. The study aims to determine how well these different treatment options work to control the disease.

Participants in the study will take these medications by mouth in the form of coated tablets or capsules. The study aims to determine how well this combination of drugs works to reduce cancer cells in the body. During the study, medical professionals will monitor the response to the treatment and watch for any side effects that may occur while taking the medications.

The purpose of the study is to find out whether treatment with zanubrutinib for twelve months can lead to improvement in nerve function as measured by various scales that assess strength, sensation, and ability to perform daily activities. These scales help doctors understand how well patients can move, feel sensations, and carry out everyday tasks. The study will measure whether patients improve by at least one point on at least two of these measurement scales after one year of treatment.

During the study, patients will take zanubrutinib capsules daily for up to forty-eight months. The maximum daily amount is three hundred twenty milligrams, and the maximum total amount in a day is four hundred eighty milligrams. Doctors will regularly check nerve function using the measurement scales and will also perform nerve conduction studies, which are tests that measure how well electrical signals travel through the nerves. Blood tests will be done to measure the levels of abnormal proteins and anti-MAG antibodies at twelve, twenty-four, and forty-eight months to see if the treatment is reducing these harmful substances in the blood.

During the study, participants will receive pirtobrutinib as a film-coated tablet taken by mouth along with the immuno-chemotherapy treatment. The medication will be given according to a specific schedule, with the maximum daily dose being 200 mg. The treatment period can last up to 420 days, which is approximately 14 months. Throughout the study, doctors will monitor how well the treatment is working by checking for the presence of cancer cells in the blood and bone marrow at different time points, including at 9 months, 18 months, and 24 months after starting treatment.

The study will track several important measures over time, including how long patients remain free from disease progression, how long they survive overall, and how long it takes before they need another treatment. Participants will need to attend regular study visits for evaluations and monitoring. The study requires that participants be at least 18 years old, have adequate blood counts and organ function, and be able to take oral medications. Patients must also have received vaccination against SARS-CoV-2 and will need testing before each treatment cycle if clinically indicated.

Participants in this study must have received previous treatment with medicines called BTK inhibitors that either did not work, stopped working, or caused side effects that could not be tolerated. They should also have been previously treated with a type of medicine called BCL-2 inhibitors according to local medical practice. The study will randomly assign patients to receive either DZD8586 or one of the doctor’s choice treatments. DZD8586 is given as a tablet taken by mouth daily for up to 36 months. If the doctor chooses idelalisib, it is also taken by mouth daily for up to 36 months. If the doctor chooses the combination treatment, bendamustine is given through a vein and rituximab is given through a vein for up to 24 weeks.

During the study, doctors will monitor how well the treatment controls the cancer by checking for signs of disease progression and measuring how long patients remain free from cancer growth. They will also assess overall survival, quality of life, and safety by monitoring for any side effects or health problems that may occur during treatment. Blood samples will be collected to measure the levels of DZD8586 in the body to understand how the medicine is processed.

The purpose of the study is to test the safety of different doses of Allo-QuadCAR01-T in the early phases and to find the best dose to use. In the later phase, the study aims to see how well this treatment works at controlling or eliminating the cancer. The study is divided into three parts. In the first part, called Phase Ia, different dose levels of the treatment will be tested to see if they are safe and well-tolerated. In Phase Ib, the treatment will continue to be tested for safety and the researchers will confirm the recommended dose for the next phase. In Phase II, the study will focus on measuring how effective the treatment is at making the cancer respond or disappear.

Patients in this study will need to have their disease confirmed by tissue examination and must have received at least two previous treatments, or be unsuitable for standard treatments, or have chosen not to receive them. Before receiving Allo-QuadCAR01-T, patients will undergo tests to make sure they meet the requirements, including having their tissue type matched to available treatment batches. The treatment itself is given after a short course of chemotherapy to prepare the body. During and after the treatment, patients will be monitored closely for side effects and to see how well the cancer responds. This monitoring includes blood tests, imaging scans, and other assessments to track the cancer and the immune cells over time.

The treatments used in this study include several anti-cancer medications: cytarabine, daunorubicin, etoposide, cladribine, mitoxantrone, obinutuzumab, ibrutinib, venetoclax, and fludarabine. Some patients may also receive cyclophosphamide, busulfan, or treosulfan as part of their treatment. The medications are given either through intravenous infusion or as oral tablets, depending on the specific drug.

The main purpose of this study is to determine if less intensive treatment can be as effective as standard treatment in patients who show no signs of remaining disease after initial therapy. The study will monitor patients’ survival, side effects, and whether the disease returns after treatment. Participants will be followed for several years to evaluate the long-term effectiveness of these treatment approaches.

Participants in the study will be randomly assigned to receive either the new medication BGB-16673 or one of the other treatment options. The study will monitor the participants over a period to see how long they live without the disease getting worse. This is known as progression-free survival. The study will also look at other factors, such as overall survival, which is the time from the start of the study until death from any cause, and the response of the disease to the treatment. The study will also track any side effects that occur during the treatment.

The study aims to provide more information about the effectiveness of BGB-16673 compared to the other treatment options. It will help determine which treatment might be better for patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma who have previously been treated with certain other cancer medications. The study is expected to continue until 2030, with recruitment starting in 2025.

The purpose of the study is to investigate the safety of different ways to start treatment with Sonrotoclax, a new medication, in patients with blood cancers. The study will look at how often and how severe a condition called tumor lysis syndrome (TLS) occurs. TLS is a potential complication that can happen when cancer cells break down quickly. The study will also monitor any side effects that participants might experience during the treatment.

Participants in the study will receive the medications orally, meaning they will take them by mouth. The study will follow a specific schedule to gradually increase the dose of Sonrotoclax to see how well patients tolerate it. The study aims to ensure that the treatment is safe and to find the best way to start the medication to minimize any risks. The study is expected to continue until early 2026, with recruitment starting in mid-2025.

The purpose of the study is to compare the effectiveness of these treatments in patients who have not received prior treatment for their CLL or SLL. The study will look at how long patients live without their disease getting worse, which is known as progression-free survival. The trial will also explore how the treatment duration can be adjusted based on the measurement of individual residual disease, which refers to the small number of cancer cells that might remain after treatment.

Participants in the study will receive one of the treatment combinations for a set number of cycles. The study will monitor various outcomes, including the overall response to the treatment, the duration of the response, and the time until the next treatment is needed. Safety will also be closely monitored by tracking any adverse events. The study aims to improve treatment outcomes by tailoring the duration of therapy to each patient’s needs.

The purpose of the study is to see how well patients respond to the treatments. Participants will be divided into two groups. One group will receive the combination of Sonrotoclax and Zanubrutinib, and the other group will receive only Zanubrutinib. The study will monitor the patients over a period to see how many achieve a complete response, which means the cancer is no longer detectable, or a complete response with incomplete bone marrow recovery, which means the cancer is not detectable but the bone marrow has not fully recovered.

Throughout the study, participants will take the medications orally, in the form of tablets or capsules. The trial will last for several months, and the health of the participants will be closely monitored to ensure their safety and to assess the effectiveness of the treatments. The study aims to provide valuable information on whether the combination of Sonrotoclax and Zanubrutinib offers better outcomes for patients with Chronic Lymphocytic Leukemia compared to Zanubrutinib alone.

The purpose of the study is to see how well the combination of Lisaftoclax and Acalabrutinib works in treating patients with newly diagnosed CLL or SLL. Participants in the study will be randomly assigned to receive either the new drug combination or the standard immunochemotherapy. The study will monitor the participants over a period of time to see how their disease progresses and to check for any side effects from the treatments.

Throughout the study, participants will receive regular check-ups and tests to track their health and the effectiveness of the treatment. The study aims to provide valuable information on whether the new drug combination can offer a better treatment option for patients with CLL or SLL. The study is expected to continue for several years to gather comprehensive data on the outcomes of the treatments being tested.

The purpose of the study is to determine how safe and tolerable AZD0486 is when given to patients with these types of blood cancers. The study will also find the best dose to use in future research. Participants will receive the treatment either through an infusion into a vein or an injection under the skin. The study will be conducted in several phases, starting with a smaller group of participants to assess safety, and then expanding to include more participants to further evaluate the treatment’s effectiveness.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The trial aims to provide valuable information on how well AZD0486 works in treating these blood cancers and to ensure that it is safe for patients. The study is expected to continue until 2026, with recruitment starting in 2025.

The study is divided into two phases. In the first phase, different doses of IDP-121 will be given to patients to determine the highest dose that can be safely administered. This is known as the dose-escalation phase. In the second phase, the study will focus on how effective the recommended dose is in treating the cancers. This phase will look at how many patients respond to the treatment and how long the response lasts.

Throughout the study, patients will receive regular check-ups to monitor their health and the effects of the treatment. This includes checking vital signs, conducting physical exams, and performing various tests like blood tests and heart monitoring. The study aims to gather information on how the treatment affects the body and how long patients can live without the cancer getting worse. Safety and any side effects will also be closely observed to ensure the well-being of the participants.

The purpose of the study is to evaluate if this combination of drugs can help achieve a significant reduction in cancer cells in the bone marrow, which is a sign of a good response to treatment. The study will follow patients over a period of time to monitor their response to the treatment, including how long the response lasts and whether the cancer returns. Patients will receive the treatment for a maximum of 25 weeks, and their health will be closely monitored throughout the study.

Participants in the study will be randomly assigned to receive either the combination of Venetoclax and Rituximab or a placebo. The study aims to gather information on the overall effectiveness of the treatment, the quality of life of the participants during the treatment, and any side effects they may experience. The trial will also explore new ways to predict how well patients will respond to the treatment using advanced techniques like machine learning and by studying gut bacteria. The study is expected to continue until 2027.

Participants in the study will receive either the TL-895 treatment alone or in combination with Navtemadlin. The study will observe how the cancer responds to these treatments over time. Some participants will receive a placebo to compare the effects. The trial is divided into different parts, with some focusing on those who have not been treated before and others on those whose cancer has returned or not responded to previous treatments.

The study will monitor participants for any changes in their condition and any side effects they might experience. The goal is to determine the overall response rate, which means how many people see a reduction in their cancer symptoms. The trial will also look at how long any positive effects last and assess the safety of the treatments. This research aims to find more effective ways to treat these types of blood cancers and improve outcomes for patients in the future.

The purpose of this study is to evaluate how well the new combination of acalabrutinib, venetoclax, and obinutuzumab works compared to the traditional chemotherapy options. Participants in the study will be randomly assigned to receive either the new combination treatment or one of the standard chemotherapy treatments. The study will monitor participants over a period of time to assess the progression of the disease and any side effects experienced. The medications will be administered either orally or through intravenous infusion, depending on the specific drug.

This trial is designed for individuals who have not received prior treatment for their CLL and do not have certain genetic mutations, specifically the del(17p) or TP53 mutation. The study aims to provide valuable information on whether the new treatment combination can offer better outcomes for patients with CLL compared to existing chemotherapy options. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather data on the effectiveness of the treatments.

Participants in the study will receive these medications through a method called subcutaneous injection, which means the medicine is given under the skin. The study will last for a period of up to 24 months, during which participants will be closely monitored. The researchers will look at how well the cancer responds to the treatment and will also keep track of any side effects that may occur. The study aims to improve understanding of how these medications can be used together to treat CLL more effectively.

Throughout the study, participants will have regular check-ups to assess their health and the progress of the treatment. This includes monitoring the presence of cancer cells in the blood and bone marrow, as well as evaluating overall health and quality of life. The study will also gather information on how the body processes belimumab, which is known as pharmacokinetics. The ultimate goal is to find a more effective treatment option for patients with CLL who have limited options due to the return or resistance of their disease.

Participants in the study will receive either acalabrutinib or another treatment selected by their doctor. The study will monitor how patients respond to the treatment over a period of time, which could last up to 72 weeks. The study will also look at how often patients need to stop their treatment due to heart-related issues or other serious side effects. Additionally, the study will track the overall survival of patients, which means the time from starting the study to the time of death from any cause.

The study aims to provide valuable information on the effectiveness and safety of acalabrutinib for patients with CLL and heart problems. By comparing it to other treatments, researchers hope to understand better which option might be more beneficial for these patients. The results could help guide future treatment decisions for people with similar health conditions.

The purpose of this study is to evaluate how effective Ibrutinib is in treating AIHA in patients with CLL, SLL, or CLL-like conditions. Participants in the study will take Ibrutinib orally, and the study will be conducted over a period of time with several cycles of treatment. Each cycle lasts 28 days, and the study will assess the response of AIHA after 6 cycles. Additionally, the study will look at the response after 3 and 12 cycles, as well as other factors like the duration of the response, the need for blood transfusions, and any side effects related to the treatment.

Throughout the study, researchers will also monitor the overall health and quality of life of the participants, as well as specific responses related to CLL. The study aims to provide valuable information on the effectiveness and safety of Ibrutinib for patients with these conditions, helping to improve treatment options in the future.

The purpose of this study is to evaluate how effective and safe the combination of zanubrutinib and obinutuzumab is for patients who have not received treatment for their CLL or SLL before. The study will compare two different schedules for administering obinutuzumab to see which is more effective. Participants will receive these treatments over a period of time, and their health will be monitored to see how well the cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will look at various outcomes, such as the rate of complete remission, which means the cancer is no longer detectable, and how long patients live without the disease getting worse. They will also assess the overall safety of the treatments and any potential side effects. This study aims to provide valuable information on the best way to treat these types of blood cancers with the combination of zanubrutinib and obinutuzumab.

The purpose of the study is to evaluate how well these treatment combinations work in reducing the amount of cancer cells in the blood, which is referred to as the minimal residual disease (MRD) response rate. Participants in the study will receive one of the treatment combinations and will be monitored over a period of time to assess the effectiveness of the treatment. The study will also look at other outcomes such as progression-free survival, overall survival, and the impact of the treatments on quality of life.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the response of their cancer to the treatment. The study will help determine which treatment combination is more effective and safer for patients with previously untreated CLL. This information could be valuable in guiding future treatment decisions for this type of cancer.

The purpose of the study is to find the best dose of Rapcabtagene Autoleucel and to understand its safety and effectiveness in treating these cancers. The study is divided into two phases. In the first phase, researchers aim to determine the appropriate dose and assess the safety of the treatment, both alone and in combination with Ibrutinib for CLL/SLL. The second phase focuses on evaluating how well the treatment works in reducing or eliminating the cancer. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also look at how the treatment affects the cancer over time. This research is important for developing new ways to treat these types of blood cancers and could lead to more effective therapies in the future.

The purpose of the study is to evaluate how effective this combination of medications is in reducing the amount of cancer cells to a very low level, known as minimal residual disease, in patients with CLL. The study will follow patients through a course of treatment that can last up to 24 months. During this time, the effectiveness of the treatment will be monitored to see if the cancer cells become undetectable.

Participants in the study will receive the medications in a specific sequence, starting with Venetoclax, followed by Rituximab, and then Ibrutinib. The goal is to achieve the best possible response in reducing cancer cells, which will be checked using a method called 6-color cytofluorimetry, a technique that helps to detect very small amounts of cancer cells in the bone marrow. The study aims to see if this combination can help patients achieve a state where the cancer is not detectable, which is a positive outcome for those with CLL.

The purpose of the study is to understand how the genetic makeup of the cancer cells changes over time in patients with CLL who have these TP53 mutations. Participants in the study will receive ibrutinib as their first treatment for CLL. The study will monitor the patients at various time points, starting from the beginning of the treatment and continuing at weeks 2, 4, 12, 24, 48, 72, and 96, and then every year until the study ends or the disease progresses.

Throughout the study, researchers will observe how the size of the TP53 mutated subclones, which are small groups of cancer cells with these specific mutations, changes in response to the treatment. This information will help in understanding the effectiveness of ibrutinib in managing CLL with TP53 aberrations and may provide insights into better treatment strategies for this condition in the future.

The purpose of the study is to evaluate the effectiveness of this treatment combination in reducing the presence of cancer cells in the bone marrow. Participants will receive Ibrutinib over a period of 24 cycles, and Obinutuzumab will be given during specific cycles. The study will monitor the patients for 30 days after the completion of the treatment to assess the reduction of cancer cells.

This trial aims to provide valuable information on how well this treatment works for patients with Chronic Lymphocytic Leukemia. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the treatment’s effectiveness. The study will help in understanding whether this combination of medications can be a beneficial option for treating CLL.

The purpose of the study is to evaluate how effective the combination of Ibrutinib and Venetoclax is in reducing the number of cancer cells to very low levels, a state known as minimal residual disease (MRD) negativity. This means that the cancer cells are reduced to such a low number that they are almost undetectable. The study will follow a specific plan where patients will receive these medications and be monitored to see how well the treatment works over time.

Participants in the study will take the medications as directed and will have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide more information on how well this combination of medications can help patients with relapsed or refractory CLL. The trial is open-label, meaning both the researchers and participants know which treatment is being given, and it is not controlled by a placebo group.

Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.

The treatments being tested include a combination of three medications: Acalabrutinib, Obinutuzumab, and Venetoclax, referred to as GAVe, and a combination of two medications: Obinutuzumab and Venetoclax, referred to as GVe. Acalabrutinib is a type of medication known as a BTK inhibitor, which helps block certain signals that cancer cells need to grow. Obinutuzumab is a monoclonal antibody that targets specific proteins on cancer cells, and Venetoclax is a BCL2 inhibitor that helps to kill cancer cells by affecting their survival mechanisms.

Participants in the study will be randomly assigned to receive either the GAVe or GVe treatment. The study will monitor how long patients remain free from disease progression, as well as other outcomes like overall response to treatment and survival rates. The trial will also involve regular check-ups and assessments to track the effectiveness and safety of the treatments over time. The goal is to determine if the addition of Acalabrutinib to the existing treatment of Obinutuzumab and Venetoclax can provide better outcomes for patients with high-risk CLL.

The purpose of the study is to evaluate how effective these medications are in treating patients with CLL or SLL who have not achieved complete remission or still have detectable cancer cells in their bone marrow after initial treatment. The study will begin with an induction phase using venetoclax and ibrutinib, followed by an intensification phase with obinutuzumab for those who need further treatment. The trial aims to see if this approach can help patients achieve a state where no cancer cells are detectable in the bone marrow.

Participants in the study will receive treatment over a period of time, with regular check-ups to monitor their response to the medications. The study will track various outcomes, including the level of cancer cells in the bone marrow and overall survival rates. The trial is expected to continue until 2027, providing valuable information on the effectiveness of this treatment combination for CLL and SLL patients.

Participants in the study will receive the medication Lisaftoclax either by itself or together with one of the other mentioned drugs. The study will monitor how well patients tolerate the treatments and will look for any side effects. The goal is to find the best dose of Lisaftoclax that can be safely given to patients. The study will also assess how effective the treatments are in controlling the disease.

Throughout the study, patients will be closely monitored by healthcare professionals. The study will involve regular check-ups and tests to track the progress of the disease and the patient’s response to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The study aims to provide valuable information that could lead to better treatment options for people with CLL and SLL.

The purpose of the study is to determine the safety and appropriate dosage of acalabrutinib for patients with these conditions. Participants in the trial will receive the medication in increasing doses to find the most effective and safe amount. The study will also look at how the body processes the medication and its effects on the disease. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, participants will be monitored closely to observe how their bodies respond to the treatment. This includes regular check-ups and tests to ensure their safety and to gather information on the medication’s impact. The trial aims to provide valuable insights into the potential benefits of acalabrutinib for treating these specific types of leukemia and related conditions.

Participants in the study will receive treatment with Venetoclax and Acalabrutinib over a series of cycles. The study aims to assess how well the treatment works in reducing the presence of cancer cells in the bone marrow after 26 cycles. The study will also monitor the overall response to the treatment, including how long patients remain free from disease progression and their overall survival. Additionally, the study will explore the impact of the treatment on patients’ quality of life and any side effects experienced during the trial.

This trial is designed to provide valuable information on the potential benefits of using Venetoclax and Acalabrutinib for patients with relapsed CLL. By participating in this study, researchers hope to gain insights into the effectiveness of this treatment combination and its impact on patients’ health and well-being. The study will continue until the end of 2032, with ongoing assessments to ensure the safety and efficacy of the treatment.